ALZ-NET Educational Events and Engagement Opportunities

ALZ-NET is committed to providing continuing education opportunities for patients, families, health care providers and researchers across all communities. ALZ-NET is a resource for evidence gathering, information sharing and education to help improve brain health outcomes.

Continuing medical education (CME) opportunities and credits may be available.

Upcoming ALZ-NET educational opportunities

Join us at the Alzheimer’s Association International Conference (AAIC®): ALZ-NET Specific Activities

Audience: Health Systems, Health Care Providers, and Researchers
Date: July 28 – August 1, 2024
CME/CEU: Available
Registration for AAIC

Join us in Philadelphia, United States and online for AAIC 2024, July 28 – August 1, where the world’s leading basic scientists, clinical researchers, early-career investigators, clinicians and the care research community will share breaking research discoveries that will lead to methods of prevention and treatment and improvements in diagnosis for Alzheimer’s disease.

On Wednesday, July 31st at 2:00p.m. – 3:30p.m. EST, join us for an engaging session on “Case-Based Learning: Amyloid Related Imaging Abnormalities (ARIA) in Patients Being Evaluated for or Treated with Amyloid Targeting Therapies.” This session will explore real-world cases of ARIA focusing on patient selection and risk-benefit discussions, detection and management of ARIA, and acute presentations of ARIA in the ER. Speakers include Stephen Salloway, M.D., Lawren VandeVrede, M.D., Tammie Benzinger, M.D., Ph.D., and Jeffrey Saver, M.D.

For those attending AAIC 2024 in person, there are multiple opportunities to meet the ALZ-NET team. One opportunity is to stop by the ALZ-NET booth in the exhibit hall. Members of the team will be there throughout the week. Another opportunity is to attend the ALZ-NET Reception on Wednesday, July 31st from 6p.m. – 8p.m. EST. Attendees will be able to socialize and network with other participating site investigators and staff, as well as the ALZ-NET operations and leadership team. If you would like to attend the reception, please RSVP.

ALZ-NET educational opportunities for Health Systems, Health Care Providers, and Researchers

ALZ-NET International Case Study Series: Exploring Eligibility (Episode 2)

Audience: Health Systems, Health Care Providers, and Researchers
Date: June 7, 2024
CME/CEU: Available
Watch the video

Watch episode 2 of the ALZ-NET International Case Study Series, which will explore patients’ eligibility for treatment. Two cases will be discussed in episode 2. Case 1: 82-year-old female with a history of hypertension who was admitted for a stroke in 2022. She has had progressive memory complaints since 2017. Currently CDR 0.5, MMSE 21, APOE-Ɛ3/4. Amyloid positivity confirmed by cerebrospinal fluid (CSF). Baseline MRI has a small, chronic right frontal cortical infarction. Case 2: 60-year-old female who is APOE-Ɛ4/4 mild AD, confirmed by spinal tap. Started aducanumab (Aduhelm®) with subsequent moderate ARIA-E and resolution with rechallenge. No subsequent ARIA.

ALZ-NET International Case Study Series: Exploring Eligibility (Episode 1)

Audience: Health Systems, Health Care Providers, and Researchers
Date: May 1, 2024
CME/CEU: Available
Watch the video

Watch episode 1 of the ALZ-NET International Case Study Series, which will explore the eligibility of patients for treatment. Two cases will be discussed in Episode 1. Case 1: 89-year-old male with amnestic MCI, amyloid positive, functionally intact, and very interested in lecanemab (Leqembi®). Should he get lecanemab (Leqembi®) even though he is outside the age of 85? How do we balance the risk of Limbic-predominant age-related TDP-43 encephalopathy (LATE) with AD in patients in their late 80s? Case 2: 69-year-old female with hyperlipidemia and diagnosis of mild dementia due to suspected AD (biomarker testing revealed positive amyloid PET).

A New Era of Alzheimer’s Therapeutics: Biomarkers, AI for ARIA Detection, and PET Neuroimaging, presented by the ASNR Alzheimer’s, ARIA & Dementia Study Group

Audience: Health Systems, Health Care Providers, and Researchers
Date: November 8, 2023
CME/CEU: Available
Watch the video

Educational webinar hosted by ASNR, planned and presented by the Alzheimer’s, ARIA and Dementia Study Group. Understand options for fluid and imaging biomarkers in defining Alzheimer’s disease and understand how this may precede the subsequent clinical syndrome of Alzheimer’s dementia. Describe new AI tools for ARIA detection. Understand new options for applying brain PET in clinical practice to detect Alzheimer’s disease biomarkers. Discuss the neuroimaging pathway for patients with suspected Alzheimer’s disease through clinical case examples. Understand recent updates on disease modifying therapies, including ARIA risk factors and grading. Learn about AI tools that can assist in ARIA surveillance.

Alzheimer Disease, ARIA & Dementia Study Group Webinar: Practical Reflections for Lecanemab

Audience: Health Systems, Health Care Providers, and Researchers
Date: August 16, 2023
CME/CEU: Available
Watch the video

Educational webinar hosted by ASNR, planned and presented by the Alzheimer’s, ARIA and Dementia Study Group. Understand the implications of lecanemab (Leqembi®) therapy for Alzheimer’s disease in the US. Describe how patients undergoing Alzheimer’s disease therapy with lecanemab (Leqembi®) might need radiology services, including brain MRI, lumbar puncture, and Amyloid PET. Compare strategies for different healthcare environments such as academic practice, hybrid academic/private practice, private practice, and geographical/regional differences.

AAIC 2023: A Real-World Data Platform to Inform the Future of Alzheimer’s Research, Treatment and Care

Audience: Health Systems, Health Care Providers, and Researchers
Date: July 19, 2023
CME/CEU: Not Available
Watch the video

ALZ-NET Study Team Investigators and ALZ-NET Site Investigators presented an update on ALZ-NET at the 2023 Alzheimer’s Association International Conference®. Hear examples directly from clinicians operating ALZ-NET within their clinical practices and how they are integrating clinical care and research.

Engaging Health Systems in ALZ-NET: Transforming Clinical Practice, Research, Treatment and Care

Audience: Health Systems, Health Care Providers, and Researchers
Date: June 27, 2023
CME/CEU: Not Available
Watch the video

Clinicians and providers face many challenges in managing patients with dementia. The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) is a resource to collect real-world data to accelerate research, transform clinical care practice and improve brain health outcomes.

Alzheimer’s Disease and Amyloid-Related Imaging Abnormalities

Audience: Health Systems, Health Care Providers, and Researchers
Date: March 20, 2023
CME/CEU: Available
Watch the video

Learn to recognize the amyloid-related imaging abnormalities (ARIA) associated with Alzheimer’s disease, including risk factors, clinical presentation and management. The webinar is sponsored by the ACR® Commission on Neuroradiology.

An Introduction to Amyloid-Related Imaging Abnormalities (ARIA) and Its Management

Audience: Health Systems, Health Care Providers, and Researchers
Date: July 15, 2021
CME/CEU: Available
Watch the video

Over the past decade since amyloid-modifying therapeutic agents have entered Alzheimer’s disease (AD) clinical trials, the occurrence of magnetic resonance imaging (MRI) abnormalities has required careful consideration by academic investigators, pharmaceutical companies and regulatory authorities. MRI signal changes, thought to represent “vasogenic edema” (VE) and cerebral microhemorrhage (mH), were first observed in trials with monoclonal antibodies against amyloid-beta, and have since been associated with other amyloid-modifying therapies, despite differences in the proposed mechanisms of action, indicating some commonality in effect. Amyloid imaging related abnormalities (ARIA) have been reported in clinical trials using multiple therapeutic avenues to lower amyloid-beta burden in Alzheimer’s disease (AD). ARIA risk will need careful consideration but can be successfully managed by clinicians and radiologists in patients using anti-amyloid treatments.

Additional opportunities for health systems, health care providers, and researchers

Future scientific meetings

Attend an upcoming in-person or virtual conference to learn and network within the dementia science community – one of the many year-round opportunities offered by the Alzheimer’s Association.

Join ISTAART

The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) is an inclusive global network of scientists, clinicians, and dementia professionals. Members of this professional organization share common goals: the pursuit of knowledge, collaboration, and breakthroughs to advance the research and treatment of Alzheimer’s disease and other dementias.

ISTAART Voices

ISTAART Voices is a new podcast that navigates the intricate world of dementia research, practice, and treatment. Join us as we explore the latest research in conversation with study authors from the Alzheimer’s & Dementia® journal family. You can earn Continuing Medical Education (CME) and Continuing Education (CE) at no cost when you listen to this podcast.

Educational events for patients and caregivers

An Introduction to Real-World Data & Real-World Evidence: A Virtual Training Series for the Patient Community

Audience: Patients and Caregivers
Date: October 2020 - March 2021
CME/CEU: Not Available
Watch the webinars

Have you been hearing about Real-World Evidence (RWE) and Real World Data (RWD) and wondering what they are or how they might impact patients and care? The National Health Council (NHC) and the Duke-Margolis Center for Health Policy provide a webinar series that is free and open to all. It is intended for patients, patient group staff, and others interested in learning about RWD and RWE.

Additional community events and support

The Alzheimer’s Association offers a variety of in-person and virtual events across communities. Please find more local programs and online resources in the Alzheimer’s Association & AARP Community Resource Finder or contact our 24/7 Helpline (800.272.3900) for details.